-+ 0.00%
-+ 0.00%
-+ 0.00%

What Butterfly Network Doubters Got Wrong Before A 203% Rally

Simply Wall St·10/25/2026 19:25:27
語音播報

If Butterfly Network was on your watchlist instead of in your portfolio, the missed upside probably stings. For Butterfly Network shareholders, the return over the past year was 203.1%, including dividends. That kind of move tempts you to ask what was visible back on 23 October 2025, before FDA clearances, new licensing deals, and fresh analyst coverage hit the headlines. If you rewind to that starting point, how confident could you really be that AI driven ultrasound and recurring software revenue would be the right core thesis?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

This theme extends beyond Butterfly Network. See which of 34 healthcare AI stocks may still merit a closer look.

The Two Butterfly Network Stories Investors Had To Balance

The shares cost US$2.22 at the start of the period, and anyone looking at Butterfly Network then had to choose between two very different stories that both sounded reasonable.

On the optimistic side, the Fair Value of US$3.19 rested on the idea that Compass AI, Butterfly Garden apps and HomeCare pilots could support recurring digital income, with future revenue rising 15.8% a year and margins improving from heavy losses toward the wider medical equipment sector.

The more cautious Fair Value of US$2 reflected assumptions of 14.0% annual revenue growth and a future P/E of 47.3x, and it also highlighted risks from delayed enterprise deals, persistent cash burn and the possibility of further shareholder dilution.

NYSE:BFLY 1-Year Stock Price Chart
NYSE:BFLY 1-Year Stock Price Chart

What The Results Changed For The Butterfly Network Thesis

The clearest factual update was Q2 2026, when Butterfly Network reported revenue of US$32.612 million and a smaller net loss of US$12.91 million compared with a year earlier. Net margin improved from a loss of 59.2% to a loss of 39.6%, which supported the optimistic case on scale and gross efficiency but still left profitability unproven.

The lesson to take elsewhere is simple. When a story leans on future margin improvement, track the reported net margin line every quarter and test whether losses are narrowing in step with that narrative.

What Butterfly Network's Run Leaves New Buyers Paying For

Today's Butterfly Network share price of US$6.76 sits well above where this Narrative's Fair Value estimate places it, based on the author’s own assumptions and risk trade offs rather than any fixed truth.

The argument leans on ultrasound on chip, Compass AI and a long cash runway. Anyone paying today's price has to judge whether future funding needs really stay low enough that dilution risk remains contained.

"In a nut shell, I saw Butterfly Network as a medical break through and bought a few hundred shares at a $1.55/shr. and the following news confirmed my reasoning of buying; On November 17, 2025, Butterfly Network’s subsidiary signed a five-year co-development and licensing agreement with Midjourney for exclusive access to its semiconductor-based ultrasound technology, securing a US$15 million upfront payment, US$10 million annual license fees, and further milestone and revenue-sharing potential."

One Narrative disagrees with today's price. → See where this Narrative says Butterfly Network should trade

Go Straight To The Source

The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?

  • Company 1 - 32% below our estimate - uses a growing super app user base to deepen engagement across credit and commerce.
  • Company 2 - 33% below our estimate - ties premium AI chips to a software stack customers rely on for large training runs.
  • Company 3 - 42% below our estimate - folds a new regional lender into an earnings engine built on low cost deposits.

Three companies from the same screener. Open the full list of 29 companies trading below our fair value estimates →